Aesculap Implant Systems, LLC has a new interbody system for ACDF (anterior cervical discectomy and fusion) procedures.
New Spine System From Aesculap
1 min read Premium comments
Secondary
The company says the CeSpaceXP, “fuses two proven materials, an innovative PlasmaporeXP osteoconductive porous Titanium coating and a PEEK-Optima radiolucent core, that delivers enhanced implant stability, artifact-free imaging, and an optimal scaffold for cervical fusion procedures.”
According to the June 18, 2013 announcement, the system’s design advantages are the result of 30 years of innovation in spinal technology and over 20 years of success in applying Plasmapore coatings to titanium orthopedic and spine implants. “Drawing on the success of Plasmapore, Aesculap developed PlasmaporeXP, an osteoconductive porous Titanium coating that can be applied to PEEK spinal implants. PlasmaporeXP is an innovative surface enhancing technology with proven biocompatibility.”
Bob Spiro, Ph.D., vice president of Aesculap Biologics and expert in immunology and tissue regeneration said the coating found on the implant, “provides the ideal surface composition and architecture for direct bone contact, resulting in higher mechanical strength and improved implant stability.”
The system is an interbody fusion device designed for use with autogenous bone graft and intended for spinal fusion procedures at one level in the cervical spine from C3 – C7.
The company says the implant has a distinctive interbody design for ACDF procedures and enhances stability and increases migration resistance through the roughened surface area provided by the coating. The system has a comprehensive selection of instrumentation and 30 size options to ensure the best possible fit to patient anatomy and intraoperative flexibility. The CeSpaceXP has excellent imaging properties, incorporating the benefits of the PlasmaporeXP coating, which clearly delineates implant contours during imaging, with x-ray marker pins for intraoperative positioning and verification.
To view an animation of the system, click here.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.